Benchmark Holdings PLC Trading Statement (3051P)
October 18 2021 - 1:00AM
UK Regulatory
TIDMBMK
RNS Number : 3051P
Benchmark Holdings PLC
18 October 2021
18 October 2021
Information within this announcement is deemed by the Company to
constitute inside information under the Market Abuse Regulations
(EU) No. 596/2014.
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Trading Update and Notice of Results
FY21 Results expected to be significantly ahead of market
expectations
Continued good momentum across all business areas
Benchmark, the aquaculture biotechnology business, is pleased to
provide an update ahead of its full year results for the year ended
30 September 2021, which will be announced on 29(th) November
2021.
Following positive financial results in Q3 2021, the Company
maintained this momentum in Q4 2021 and has delivered a stronger
than expected trading performance across its three business areas
driven by the Group's continued strong commercial focus,
disciplined cost control and further recovery in the Company's end
markets. The Group's Advanced Nutrition business area has continued
to deliver excellent year on year growth while the Group's Genetics
business area delivered a strong end to the year, and in the
Group's Health business area, the Company achieved its first
revenues from its sea lice treatment, Ectosan (R) Vet and
CleanTreat (R); all business areas delivered above the Board's
expectations in September.
As a result, whilst still subject to audit, the Group's Adjusted
EBITDA for FY21 is expected to be significantly ahead of the
current market consensus which is GBP15.9m.
Trond Williksen, CEO, commented:
"We are pleased by the continuing momentum in the business,
which reflects the benefits of our clear commercial focus, having
streamlined the organisation, our continued disciplined approach to
cost control and good demand for our products in our recovering
markets.
"As a focused aquaculture biotechnology company with three
strong business areas, we are well positioned to capture market
opportunities and deliver profitable growth."
Notice of Results and details of analyst / investor call
The Company will announce its full year results on 29 November
2021. Trond Williksen, Chief Executive Officer and Septima Maguire,
Chief Financial Officer will host a webcast for analysts and
institutional investors on that day at 8:30am UK time. To register
your interest, please contact benchmark@mhpc.com .
Enquiries
For further information, please contact:
Benchmark Holdings plc Tel: 020 3696 0630
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: 020 7260 1000
James Black, Freddie Barnfield, Duncan Monteith
MHP Communications Tel: 020 3128 8990 / 8742
Katie Hunt, Reg Hoare, Alistair de Kare-Silver
benchmark@mhpc.com
About Benchmark
Benchmark is a leading aquaculture biotechnology company.
Benchmark's mission is to enable aquaculture producers to improve
their sustainability and profitability.
We bring together biology and technology to develop innovative
products and solutions which improve yield, quality and animal
health and welfare for our customers. We do this by improving the
genetic make-up, health and nutrition of their stock - from
broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), specialist diets and
probiotics and sea lice treatments. Find out more at
www.benchmarkplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTVDLFFFBLBFBV
(END) Dow Jones Newswires
October 18, 2021 02:00 ET (06:00 GMT)
Benchmark (LSE:BMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Benchmark (LSE:BMK)
Historical Stock Chart
From Apr 2023 to Apr 2024